• HOME>
  • Investor Relations>
  • IR News>
  • Sumitomo Dainippon Pharma Announces the Approval of an Atypical Antipsychotic Blonanserin (Brand Name in Japan: LONASEN) in China

IR News

Feb. 28, 2017Print(PDF/88KB)Products

Sumitomo Dainippon Pharma Announces the Approval of an Atypical Antipsychotic Blonanserin (Brand Name in Japan: LONASEN) in China

Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka, Japan; President: Masayo Tada; "Sumitomo Dainippon Pharma") announced today that China Food and Drug Administration (CFDA) granted the import drug license for an atypical antipsychotic blonanserin (generic name, brand name in Japan: LONASEN®) for the treatment of patients with schizophrenia on February 21, 2017. The import drug license application had been submitted in August 2013.

Sumitomo Dainippon Pharma expects to make a contribution to the treatment of patients with schizophrenia in China by offering blonanserin as a new treatment option.

(Reference)

About blonanserin (brand name in Japan: LONASEN®)

Blonanserin is an atypical antipsychotic agent with novel structure, discovered by Sumitomo Dainippon Pharma.This drug blocks dopamine D2 receptors and serotonin 5-HT2A receptors. In clinical studies, this drug showed efficacy for not only positive symptoms of schizophrenia (such as hallucinations or delusions), but also negative symptoms (such as flat affect or hypobulia). In Japan it is available from Sumitomo Dainippon Pharma since April 2008 for the treatment of schizophrenia.